Novartis Pauses Rap-cel Autoimmune Studies After Three Deaths
Novartis temporarily paused screening, randomization and treatment across eight immunology and neuroscience studies of rapcabtagene autoleucel after three patients died from complications of immune effector cell-associated hemophagocytic syndrome. The pause began August 24 and…
